home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9602.ZIP
/
M9620965.TXT
< prev
next >
Wrap
Text File
|
1996-02-26
|
2KB
|
40 lines
Document 0965
DOCN M9620965
TI Factors associated with the development of Pneumocystis carinii
pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study
Group.
DT 9602
AU Lundgren JD; Barton SE; Lazzarin A; Danner S; Goebel FD; Pehrson P;
Mulcahy F; Kosmidis J; Pedersen C; Phillips AN; Hvidovre Hospital,
Denmark.
SO Clin Infect Dis. 1995 Jul;21(1):106-13. Unique Identifier : AIDSLINE
MED/96065622
AB This study examined the factors associated with the development of a
first episode of Pneumocystis carinii pneumonia (PCP) in 5,025 patients
with AIDS, including 1,976 patients with primary PCP at the time of AIDS
diagnosis and 635 with primary PCP occurring subsequently. Compared with
untreated patients, patients treated with zidovudine were at similar
risk of developing PCP during the first year of therapy but were at
greater risk after longer intervals of treatment. The following factors
were associated with an increased risk of PCP (either at the time of
AIDS diagnosis or thereafter): lack of primary PCP prophylaxis, male
homosexuality/bisexuality, diagnosis of AIDS in northern Europe, and CD4
cell count below 200 x 10(6)/L at the time of AIDS diagnosis. Patients
with severe weight loss had a 60% higher risk of developing PCP during
follow-up than those without such weight loss. Thus, the occurrence of
PCP depended on geographic location, mode of acquisition of human
immunodeficiency virus and AIDS, degree of immunodeficiency, and use of
various treatment regimens.
DE Adult Antiviral Agents/THERAPEUTIC USE AIDS-Related Opportunistic
Infections/DIAGNOSIS/DRUG THERAPY/ *EPIDEMIOLOGY Bisexuality Cohort
Studies CD4 Lymphocyte Count Europe/EPIDEMIOLOGY Female
Homosexuality, Male Human Incidence Male Middle Age Pneumonia,
Pneumocystis carinii/DIAGNOSIS/DRUG THERAPY/ *EPIDEMIOLOGY Risk
Factors Substance Abuse, Intravenous/COMPLICATIONS Support, Non-U.S.
Gov't Weight Loss Zidovudine/THERAPEUTIC USE JOURNAL ARTICLE
MULTICENTER STUDY
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).